References
- BarterPJ, BrewerHB, Jr, ChapmanMJ, HennekensCH, RaderDJ, TallAR. 2003. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol.23:160–167.
- BodenWE. 2000. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the veterans affairs high-density lipoprotein intervention trial. Am J Cardiol.86:19L–22L.
- ChoeD, LeeJ, WooS, ShinCS. 2012. Evaluation of the amine derivatives of Monascus pigment with anti-obesity activities. Food Chem.134:315–323.
- EndoA. 1988. Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors. Kiln Wochenschr.66:421–427.
- GordonDJ, ProbstfieldJL, GarrisonRJ, NeatonJD, CastelliWP, KnokeJD, JacobsDR, BangdiwalaS, TyrolerHA. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:8–15.
- HadfieldJR, HolkerJS, StanwayDN. 1967. The biosynthesis of fungal metabolites. Part II. The β-oxo-lactone equivalences in rubropunctatin and monascorubin. J Chem Soc.19:751–755.
- HirataHH, TakazumiK, SegawaS, OkadaY, KobayashiN, ShigyoT, ChibaH. 2012. Xanthohumol, a prenylated chalcone from Humulus lupulus L., inhibits cholesteryl ester transfer protein. Food Chem.134:1432–1437.
- JeonJ, JungH, KimJH, KimYO, YounSH, ShinCS. 2008. Effect of the monascus pigment threonine derivative on regulation of the cholesterol level in mice. Food Chem.107:1078–1085.
- JungH, KimC, KimK, ShinCS. 2003. Color characteristics of monascus pigments derived by fermentation with various amino acids. J Agric Food Chem.51:1302–1306.
- KimC, JungH, KimYO, ShinCS. 2006. Anti-microbial activities of amino acid derivatives of monascus pigments. FEMS Microbiol Lett.264:117–124.
- KimJH, KimHJ, JungH, KimC, KimYO, JuJY, ShinCS. 2007. Development of lipase inhibitors from various derivatives of monascus pigment produced by Monascus fermentation. Food Chem.101:357–364.
- KuromoM, NakanishiK, ShindoK, TadaM. 1963. Biosynthesis of monascorubrin and monascoflavin. Chem Pharm Bull.11:358–362.
- LamCK, ZhangZ, YuH, TsangS-Y, HuangY. 2008. Apple polyphenols inhibit plasma CETP activity and reduce the ratio of non-HDL to HDL-cholesterol. Mol Nutr Food Res.52:950–958.
- MohammadpurAH, AkhlaghiF. 2013. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin Pharmacokinet. 52:615–626.
- Moll HR, Farr DR. 1976. Red pigment and process. US Patent 3,993,789.
- RaderD, deGomaEM. 2014. Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med.65:385–403.
- RanallettaM, BieriloKK, ChenY, MilotD, ChenQ, TungE, HoudeC, EloweNH, Garcia-CalvoM, PorterG, et al. 2010. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res.51:2739–2752.
- ShahPK. 2007. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J.28:5–12.
- ShinkaiH. 2012. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag.8:323–331.
- ShulerML, KargiF. 2002. Bioprocess engineering. 2nd ed.New Jersey (NJ): Prentice Hall PTR.
- ZernT, WestKL, FernandezML. 2003. Garpe polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J Nutr.133:2268–2272.